查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1874004

細胞株開發市場

Cell Line Development Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

2024年細胞株開發市場價值為77.7億美元，預計到2031年將成長至186.2億美元，2031年至2031年的複合年成長率預計為13.3%。細胞株工程的持續創新和細胞株技術的重大進步預計將成為該市場的主要趨勢。

細胞株開發市場分析

細胞系建構對於評估毒性、進行體外試驗以及確定新藥療效至關重要。這個過程最大限度地降低了臨床試驗中藥物失敗的風險，從而節省了時間、金錢和資源。在細胞株建構過程中，會生產重組蛋白，包括疫苗、融合蛋白、生長因子、酵素、雙特異性抗體和單株抗體，以及用於開發癌症免疫療法的創新方法。研究人員正在探索如何簡化生物治療藥物發現和候選藥物篩選的早期階段，以降低細胞株的相關成本。這個高效過程能夠快速生成並篩選出大量生產高品質重組蛋白的細胞系，同時儘早淘汰活性較低的克隆候選株。細胞株建構技術的進步加快了各種候選藥物在初始階段的測試，從而節省了時間和成本。

此外，參與藥物研發和細胞株開發的公司之間的合作正在進一步推動產業發展。例如，Cytiva 最近收購了德國領先的病毒載體和高性能細胞系生產技術供應商 CEVEC Pharmaceuticals。 2022 年 7 月，Bio-Techne Corporation 宣布完成對 Namocell, Inc. 的收購。 Namocell 提供簡單的單細胞分選和分裝平台，能夠維持細胞的活力和完整性。 Namocell 的工具和耗材是生物治療和診斷相關工作流程中的關鍵技術，包括細胞和基因療法的開發和商業化、細胞工程、細胞株開發、單細胞基因組學、抗體發現、合成生物學和稀有細胞分離。

細胞株開發市場概覽

細胞系開發是指選擇細胞機制來生產治療性生物製劑或其他有價值的蛋白質的過程。多種表現系統，包括酵母菌、哺乳動物、植物和細菌，均可用於細胞系開發。中國倉鼠卵巢 (CHO) 細胞通常在懸浮培養中生長，是生產複雜蛋白質最常用的細胞系，隨後在生產階段被送入生物反應器中。細胞株開發的初步步驟是小規模懸浮培養，最終過渡到大規模生物反應器進行生產。細胞系在治療產品開發中的應用正在改變生物製藥行業的方方面面，從創新基因療法的研發到先進疫苗和癌症治療藥物的生產，從而創造了巨大的市場機會。

戰略洞察

細胞株開發市場的促進因素與機遇

提高疫苗產量以促進市場成長

為因應疫苗產品日益成長的需求，人們開發了多種大規模生產抗原蛋白的方法。疫苗研發人員通常遵循線性流程，包括全面的資料分析和驗證，以降低以往較高的失敗率。主要的疫苗和抗病毒藥物生產商正積極研發生產大流行候選疫苗和季節性流感疫苗的新策略。此前，大部分研發工作都集中在開發已獲許可的雞蛋培養疫苗。為了滿足即將到來的季節性流感疫苗接種需求，並為臨床試驗生產大流行疫苗原型，生產商正在提升產能，並實現雞蛋培養疫苗技術中許多以往需要人工操作步驟的自動化。因此，疫苗產量的增加可能會推動細胞株開發市場的成長。

新興市場蘊藏著巨大機遇

隨著生物製劑和生物相似藥日益受到關注，生產中對細胞系的需求也隨之成長。透過與政府機構、生物技術公司和學術機構的合作，可以促進該領域的研究和開發。此外，印度擁有技術嫻熟的勞動力，且研發成本遠低於西方國家，因此是開展細胞株開發活動的理想之地。例如，印度政府透過生物技術部 (DBT)、印度醫學研究理事會 (ICMR) 和科學技術部 (DST) 等國家級資助機構，支持發展中國家的細胞株開發。

細胞株開發市場區隔分析

細胞株開發市場分析的關鍵細分市場包括類型、產品和應用。

  • 市場按類型分為原代細胞系、雜交瘤、連續細胞系和重組細胞系，其中重組細胞株在 2023 年佔據最大的市場佔有率。
  • 按產品分類，市場分為設備、培養基和試劑，其中培養基和試劑部分在 2023 年佔最大佔有率。
  • 按應用領域分類，市場分為藥物發現、生物生產和組織工程，其中生物生產領域在 2023 年佔據最大佔有率。

細胞株開發市場的地理分析

細胞株開發市場報告的地理範圍分為五個區域：北美、亞太、歐洲、中東和非洲以及南美/南美和中美洲。

北美一直是細胞株開發市場的領導地區，其中美國在2023年仍是最大的市場。美國細胞株開發市場的成長歸功於眾多產業參與者的存在以及重塑市場格局的動態變化。主要市場參與者、學術和研究機構廣泛的研發活動，以及生物製藥和生物技術公司對創新產品日益成長的需求，都在推動北美市場的成長。此外，公共和私營部門對基因組研究的大量投入，以及醫療保健領域對先進方法整合的日益重視，以及政府和私人機構為促進精準醫療而採取的舉措，預計將進一步推動北美細胞株開發市場的成長並創造可觀的收入。由於眾多支持透過生物工程技術創造、發現或改造各種生物分子和生物體的開發措施和商業策略，醫療生物技術領域經歷了革命性的變化。生技新創企業革命也使擁有創新理念的新興公司受益，提高了收入，並鞏固了北美在全球細胞株開發市場中的地位。

細胞株開發市場報告範圍

細胞株開發市場的最新發展

細胞株開發市場評估是透過收集一手和二手研究的定性和定量資料進行的，這些數據包括重要的企業出版物、協會資料和資料庫。以下是細胞株開發市場的一些最新發展和策略：

  • 2023年1月16日，Abzena公司發表了全新的細胞株開發（CLD）平台AbZelect和AbZelectPRO，旨在加速抗體和重組蛋白生產細胞系的建構。這些平台旨在促進複雜生物藥物計畫快速推進至臨床試驗和新藥研究申請（IND）提交階段。 （資料來源：Abzena公司，新聞稿，2023年）
  • 龍沙公司推出了全新的GS Effex細胞株，用於開發效力更強的治療性抗體。該細胞株的研發旨在滿足市場對更高效治療性抗體的日益成長的需求。 GS Effex細胞株，可無縫整合到龍沙的現有平台中，具有良好的細胞生長性能，並能夠生產效力更強的治療性抗體，從而為從藥物發現到商業化生產的整個治療開發過程提供解決方案。 （資料來源：龍沙公司，新聞稿，2023年）

細胞株開發市場報告的覆蓋範圍和交付成果

這份題為《細胞株開發市場規模及預測（2021-2031）》的報告對市場進行了全面分析，涵蓋以下領域：

  • 涵蓋範圍內所有關鍵細分市場的全球、區域和國家層面的市場規模和預測
  • 市場動態，例如促進因素、限制因素和關鍵機會
  • 未來主要趨勢
  • 詳細的PEST/波特五力模型與SWOT分析
  • 全球及區域市場分析，重點在於關鍵市場趨勢、主要參與者、法規及最新發展。
  • 產業格局和競爭分析，包括市場集中度、熱力圖分析、主要參與者和最新發展動態
  • 深入的公司概況

目錄

第1章：引言

第2章：細胞株開發市場及主要結論

第3章：研究方法

  • 覆蓋範圍
  • 二手研究
  • 初步研究

第4章：細胞株開發與市場概況

  • 概述
  • PEST分析
    • 北美細胞株開發市場：PEST分析
    • 歐洲細胞株開發市場：PEST分析
    • 亞太地區細胞系開發市場：PEST分析
    • 中東和非洲細胞株開發市場：PEST分析
    • 細胞株開發市場及南美洲及中美洲PEST分析
  • 專家意見

第5章：全球細胞株開發市場及主要市場動態

  • 主要市場促進因素
    • 再生醫學的日益普及
    • 癌症發生率上升
    • 製藥及生技公司加大研發投入
  • 關鍵限制
    • 細胞株污染相關的風險
  • 關鍵機遇
    • 中等收入國家創造發展機遇
  • 未來趨勢
    • 藥物發現活動中的持續研究
  • 影響分析

第6章：細胞株開發市場及全球分析

  • 全球細胞株開發市場收入預測與分析
  • 全球細胞株開發市場（依地域分類）－預測與分析
  • 關鍵參與者的市場定位
    • 默克集團
    • 賽默飛世爾科技公司

第7章：細胞株開發市場－2031年收入及預測與類型

  • 概述
  • 全球細胞株開發市場（按類型分類），2024 年和 2031 年（市場佔有率百分比）
  • 原代細胞株
    • 概述
    • 全球原代細胞株市場收入及至2031年預測
  • 雜交瘤
    • 概述
    • 全球雜交瘤市場收入及預測至2031年
  • 連續性細胞系
    • 概述
    • 全球連續細胞系市場收入及預測（至2031年）
  • 重組細胞株
    • 概述
    • 全球重組細胞株市場收入及預測（至2031年）

第8章：細胞株開發市場分析及至2031年的預測及產品

  • 概述
  • 全球細胞株開發市場（按產品分類），2024 年和 2031 年（市場佔有率百分比）
  • 裝置
    • 概述
    • 全球設備市場收入及至2031年預測
  • 介質和試劑
    • 概述
    • 全球媒體及試劑市場收入及至2031年預測

第9章：細胞株開發市場分析及至2031年的預測與應用

  • 概述
  • 2024 年和 2031 年全球細胞株開發市場佔有率（按應用領域分類）
  • 藥物發現
    • 概述
    • 全球藥物研發市場收入及至2031年預測
  • 生物生產
    • 概述
    • 全球生物生產市場收入及至2031年預測
  • 組織工程
    • 概述
    • 全球組織工程市場收入及至2031年預測

第10章：細胞株開發市場收入及至2031年預測及地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
  • MEA
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
  • 南美洲和中美洲
    • 巴西
    • 阿根廷

第11章：新冠疫情對全球細胞株開發市場的影響

  • 北美洲
  • 歐洲
  • 亞太
  • 世界其他地區

第12章：細胞株開發市場－產業概況

  • 概述
  • 市場中各公司採取的成長策略（%）
  • 市場中各公司所進行的有機發展
  • 市場上各公司進行的非有機成長

第13章：細胞株開發市場及主要公司概況

  • Merck KGaA
  • Thermo Fisher Scientific, Inc.
  • Sartorius AG
  • SELEXIS
  • BioFactura, Inc.
  • WuXi AppTec
  • LakePharma, Inc.
  • General Electric
  • Lonza
  • Corning Incorporated

第14章：附錄

簡介目錄
Product Code: TIPHE100001196

The cell line development market was valued at US$ 7.77 billion in 2024 and is projected to grow to US$ 18.62 billion by 2031, with an anticipated CAGR of 13.3% from 2031 to 2031. Continuous innovations in cell line engineering and significant advancements in cell line technology are expected to be prominent trends in the market.

Analysis of the Cell Line Development Market

Cell line development is essential for evaluating toxicity, conducting in-vitro tests, and determining the efficacy of new drug discoveries. This process minimizes the risk of drug failure during clinical trials, thereby saving time, money, and resources. During cell line development, recombinant proteins are produced, which include vaccines, fusion proteins, growth factors, enzymes, bi-specific and monoclonal antibodies, as well as innovative methods for creating cancer immunotherapies. Researchers are exploring ways to streamline the early stages of biotherapeutic discovery and candidate selection to lower the costs associated with cell line development. This efficient process quickly generates and selects cell lines that produce high-quality recombinant proteins in large quantities while eliminating less viable clone candidates as early as possible. Technological advancements in cell line development have expedited the testing of various drug candidates in the initial phases, resulting in time and cost savings.

Moreover, companies involved in drug discovery and cell line development are collaborating, which is further propelling the industry. For instance, Cytiva recently acquired CEVEC Pharmaceuticals, a leading German technology provider for producing viral vectors and high-performance cell lines. In July 2022, Bio-Techne Corporation announced the complete acquisition of Namocell, Inc., which offers simple single-cell sorting and dispensing platforms that maintain cell viability and integrity. Namocell's tools and consumables are vital technologies in various workflows related to biotherapeutics and diagnostics, including the development and commercialization of cell and gene therapies, cell engineering, cell line development, single-cell genomics, antibody discovery, synthetic biology, and rare cell isolation.

Overview of the Cell Line Development Market

Cell line development refers to the process of selecting cellular machinery to produce therapeutic biologics or other valuable proteins. Various expression systems, including yeast, mammals, plants, and bacteria, can be utilized to develop cell lines. Chinese hamster ovary (CHO) cells, typically grown in suspension cultures, are the most commonly used for producing complex proteins, which are later utilized in bioreactors during the manufacturing phase. The initial step in cell line development involves small-scale suspension cultures, which eventually transition to large-scale bioreactors for production. The application of cell lines in generating therapeutic products is transforming every aspect of the biopharmaceutical industry, from the creation of innovative gene therapies to the production of advanced vaccines and cancer treatments, thereby creating significant market opportunities.

Strategic Insights

Drivers and Opportunities in the Cell Line Development Market

Increasing Vaccine Production to Boost Market Growth

In response to the rising demand for vaccine products, various methods for producing large quantities of antigenic proteins have been developed. Vaccine developers typically follow a linear process that includes comprehensive data analysis and validation to mitigate historically high failure rates. Major vaccine and antiviral drug manufacturers are actively working on new strategies for producing pandemic candidates and seasonal influenza vaccines. Until recently, most efforts focused on developing licensed egg-based vaccines. To meet the demands of upcoming seasonal campaigns and to create pandemic vaccine prototypes for clinical trials, manufacturers are enhancing production capacities and automating many previously manual steps in egg-based vaccine technology. Consequently, the increase in vaccine production is likely to drive growth in the cell line development market.

Significant Opportunities in Emerging Markets

As biologics and biosimilars gain more attention, the need for cell lines in production is increasing. Research and development opportunities in this area can be fostered through collaborations with government initiatives, biotech firms, and academic institutions. Additionally, India is an attractive location for cell line development activities due to its skilled workforce and lower development costs compared to Western countries. For example, the Indian government supports cell line development in developing nations through national funding organizations such as the Department of Biotechnology (DBT), the Indian Council of Medical Research (ICMR), and the Department of Science and Technology (DST).

Segmentation Analysis of the Cell Line Development Market

Key segments contributing to the analysis of the cell line development market include type, product, and application.

  • The market is segmented by type into primary cell lines, hybridomas, continuous cell lines, and recombinant cell lines, with the recombinant cell line segment holding the largest market share in 2023.
  • By product, the market is divided into equipment, media, and reagents, with the media and reagent segment capturing the largest share in 2023.
  • By application, the market is categorized into drug discovery, bioproduction, and tissue engineering, with the bioproduction segment holding the largest share in 2023.

Geographical Analysis of the Cell Line Development Market

The geographic scope of the cell line development market report is divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has been the leading region in the cell line development market, with the US being the largest market in 2023. The growth of the US cell line development market is attributed to the presence of various industry players and the dynamic conditions that have reshaped the market landscape. Key market players, extensive research and development activities by academic and research institutions, and a rising demand for innovative products from biopharmaceutical and biotechnology companies are driving growth in North America. Additionally, significant funding for genomic research from both public and private sectors, along with an increasing focus on integrating advanced methods in healthcare and government and private initiatives to promote precision medicine, are expected to further propel growth and generate substantial revenue for the North American cell line development market. The medical biotechnology sector has undergone revolutions due to numerous development initiatives and business strategies that support the creation, discovery, or modification of diverse biomolecules and organisms through bioengineering techniques. The Biotech Startup Revolution has also benefited new companies with innovative ideas, enhancing revenue generation and strengthening North America's position in the global cell line development market.

Scope of the Cell Line Development Market Report

Recent Developments in the Cell Line Development Market

The cell line development market is assessed through qualitative and quantitative data collected from primary and secondary research, including significant corporate publications, association data, and databases. Below are some recent developments and strategies in the cell line development market:

  • On January 16, 2023, Abzena launched its new cell line development (CLD) platforms, AbZelect and AbZelectPRO, aimed at accelerating the generation of production cell lines for manufacturing antibodies and recombinant proteins. These platforms are designed to facilitate the rapid advancement of complex biologic drug programs towards clinical trials and investigational new drug (IND) application submissions. (Source: Abzena Company Name, Newsletter, 2023)
  • Lonza introduced its new GS Effex cell line for developing therapeutic antibodies with enhanced potency. This cell line was created to address the growing market demand for more sophisticated therapeutic antibodies. Derived from Lonza's leading GS Xceed cell line, GS Effex integrates seamlessly into Lonza's platforms, offering good cell growth and the capability to produce therapeutic antibodies with increased potency, thus providing a solution for therapeutic development from discovery to commercial manufacturing. (Source: Lonza Company Name, Press Release, 2023)

Coverage and Deliverables of the Cell Line Development Market Report

The report titled "Cell Line Development Market Size and Forecast (2021-2031)" offers a comprehensive analysis of the market, covering the following areas:

  • Market size and forecast at global, regional, and country levels for all key market segments included in the scope
  • Market dynamics such as drivers, restraints, and key opportunities
  • Key future trends
  • Detailed PEST/Porter's Five Forces and SWOT analysis
  • Global and regional market analysis highlighting key market trends, major players, regulations, and recent developments
  • Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
  • In-depth company profiles

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Global Cell Line Development Market and By Type
    • 1.3.2 Global Cell Line Development Market and By Product
    • 1.3.3 Global Cell Line Development Market and By Application
    • 1.3.4 Global Cell Line Development Market and By Geography

2. Cell Line Development Market and Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Cell Line Development and Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Cell Line Development Market in North America: PEST Analysis
    • 4.2.2 Cell Line Development Market in Europe: PEST Analysis
    • 4.2.3 Cell line development Market in APAC: PEST Analysis
    • 4.2.4 Cell Line Development Market in MEA: PEST Analysis
    • 4.2.5 Cell Line Development Market and South and Central America PEST Analysis
  • 4.3 Expert Opinion

5. Global Cell Line Development Market and Key Market Dynamics

  • 5.1 Key Market Drivers
    • 5.1.1 Increasing Adoption of Regenerative Medicines
    • 5.1.2 Rising Prevalence of Cancer
    • 5.1.3 Growing Investment in R and D by Pharmaceutical and Biotechnology Companies
  • 5.2 Key Restraints
    • 5.2.1 Risk Associated with Cell Line Contamination
  • 5.3 Key Opportunity
    • 5.3.1 Middle Income Countries Creating Development Opportunities
  • 5.4 Future Trend
    • 5.4.1 Consistent Research in Drug Discovery Activities
  • 5.5 Impact Analysis

6. Cell Line Development Market and Global Analysis

  • 6.1 Global Cell Line Development Market Revenue Forecast and Analysis
  • 6.2 Global Cell Line Development Market, By Geography - Forecast and Analysis
  • 6.3 Market Positioning of Key Players
    • 6.3.1 Merck KGaA
    • 6.3.2 Thermo Fisher Scientific Inc.

7. Cell Line Development Market - Revenue and Forecasts to 2031 and Type

  • 7.1 Overview
  • 7.2 Global Cell Line Development Market, by Type, 2024 and 2031 (% Share)
  • 7.3 Primary Cell Line
    • 7.3.1 Overview
    • 7.3.2 Global Primary Cell Line Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.4 Hybridomas
    • 7.4.1 Overview
    • 7.4.2 Global Hybridomas Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.5 Continuous Cell Lines
    • 7.5.1 Overview
    • 7.5.2 Global Continuous Cell Lines Market Revenue and Forecast to 2031 (US$ Mn)
  • 7.6 Recombinant Cell Line
    • 7.6.1 Overview
    • 7.6.2 Global Recombinant Cell Line Market Revenue and Forecast to 2031 (US$ Mn)

8. Cell Line Development Market Analysis and Forecasts to 2031 and Product

  • 8.1 Overview
  • 8.2 Global Cell Line Development Market, by Product, 2024 and 2031 (% Share)
  • 8.3 Equipment
    • 8.3.1 Overview
    • 8.3.2 Global Equipment Market Revenue and Forecast to 2031 (US$ Mn)
  • 8.4 Media and Reagent
    • 8.4.1 Overview
    • 8.4.2 Global Media and Reagent Market Revenue and Forecast to 2031 (US$ Mn)

9. Cell Line Development Market Analysis and Forecasts to 2031 and Application

  • 9.1 Overview
  • 9.2 Global Cell Line Development Market Share by Application 2024 and 2031 (%)
  • 9.3 Drug Discovery
    • 9.3.1 Overview
    • 9.3.2 Global Drug Discovery Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.4 Bioproduction
    • 9.4.1 Overview
    • 9.4.2 Global Bioproduction Market Revenue and Forecast to 2031 (US$ Mn)
  • 9.5 Tissue Engineering
    • 9.5.1 Overview
    • 9.5.2 Global Tissue Engineering Market Revenue and Forecast to 2031 (US$ Mn)

10. Cell Line Development Market Revenue and Forecast to 2031 and Geographical Analysis

  • 10.1 North America Cell Line Development Market, Revenue and Forecast to2031
    • 10.1.1 Overview
    • 10.1.2 North America Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.1.3 North America Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.1.4 North America Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.1.5 North America Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.1.6 North America Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.1.7 US
      • 10.1.7.1 US Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.1.7.2 US Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.1.7.3 US Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.1.7.4 US Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.1.8 Canada
      • 10.1.8.1 Canada Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.1.8.2 Canada Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.1.8.3 Canada Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.1.8.4 Canada Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.1.9 Mexico
      • 10.1.9.1 Mexico Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.1.9.2 Mexico Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.1.9.3 Mexico Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.1.9.4 Mexico Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.2 Europe Cell Line Development Market Revenue and Forecast to 2031
    • 10.2.1 Europe Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.2.2 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.2.3 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.2.4 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.5 Europe Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.2.6 Germany
      • 10.2.6.1 Germany Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.6.2 Germany Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.6.3 Germany Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.6.4 Germany Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.7 UK
      • 10.2.7.1 UK Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.7.2 UK Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.7.3 UK Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.7.4 UK Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.8 France
      • 10.2.8.1 France Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.8.2 France Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.8.3 France Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.8.4 France Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.9 Spain
      • 10.2.9.1 Spain Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.9.2 Spain Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.9.3 Spain Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.9.4 Spain Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.2.10 Italy
      • 10.2.10.1 Italy Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.2.10.2 Italy Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.2.10.3 Italy Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.2.10.4 Italy Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.3 APAC Cell Line Development Market, Revenue and Forecast to 2031
    • 10.3.1 Overview
    • 10.3.2 APAC Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.3.3 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.3.4 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.3.5 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.6 APAC Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.3.7 China
      • 10.3.7.1 China Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.7.2 China Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.7.3 China Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.7.4 China Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.8 Japan
      • 10.3.8.1 Japan Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.8.2 Japan Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.8.3 Japan Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.8.4 Japan Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.9 India
      • 10.3.9.1 India Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.9.2 India Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.9.3 India Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.9.4 India Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.10 South Korea
      • 10.3.10.1 South Korea Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.10.2 South Korea Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.10.3 South Korea Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.10.4 South Korea Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.3.11 Australia
      • 10.3.11.1 Australia Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.3.11.2 Australia Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.3.11.3 Australia Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.3.11.4 Australia Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.4 MEA Cell Line Development Market, Revenue and Forecast to 2031
    • 10.4.1 Overview
    • 10.4.2 MEA Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.4.3 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.4.4 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.4.5 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.4.6 MEA Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.4.7 UAE
      • 10.4.7.1 UAE Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.4.7.2 UAE Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.4.7.3 UAE Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.4.7.4 UAE Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.4.8 Saudi Arabia
      • 10.4.8.1 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.4.8.2 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.4.8.3 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.4.8.4 Saudi Arabia Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.4.9 South Africa
      • 10.4.9.1 South Africa Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.4.9.2 South Africa Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.4.9.3 South Africa Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.4.9.4 South Africa Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
  • 10.5 South and Central America Cell Line Development Market, Revenue and Forecast to 2031
    • 10.5.1 Overview
    • 10.5.2 South and Central America Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
    • 10.5.3 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
    • 10.5.4 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
    • 10.5.5 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.5.6 South and Central America Cell Line Development Market, Revenue and Forecast to 2031, By Country (%)
    • 10.5.7 Brazil
      • 10.5.7.1 Brazil Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.5.7.2 Brazil Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.5.7.3 Brazil Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.5.7.4 Brazil Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)
    • 10.5.8 Argentina
      • 10.5.8.1 Argentina Cell Line Development Market, Revenue and Forecast to 2031 (US$ Mn)
      • 10.5.8.2 Argentina Cell Line Development Market, Revenue and Forecast to 2031, By Type (US$ Mn)
      • 10.5.8.3 Argentina Cell Line Development Market, Revenue and Forecast to 2031, By Product (US$ Mn)
      • 10.5.8.4 Argentina Cell Line Development Market, Revenue and Forecast to 2031, By Application (US$ Mn)

11. Impact Of COVID-19 Pandemic on Global Cell Line Development Market

  • 11.1 North America: Impact Assessment of COVID-19 Pandemic
  • 11.2 Europe: Impact Assessment of COVID-19 Pandemic
  • 11.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
  • 11.4 Rest of the World: Impact Assessment of COVID-19 Pandemic

12. Cell Line Development Market - Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies Done by the Companies in The Market, (%)
  • 12.3 Organic Developments Done by The Companies in the Market
  • 12.4 Inorganic Developments Done by The Companies in the Market

13. Cell Line Development Marketand Key Company Profiles

  • 13.1 Merck KGaA
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Financial Overview
    • 13.1.4 Product Portfolio
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 Thermo Fisher Scientific, Inc.
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Financial Information
    • 13.2.4 Product /Services Portfolio
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Sartorius AG
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Financial Overview
    • 13.3.4 Product Portfolio
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 SELEXIS
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Financial Overview
    • 13.4.4 Product/Service Portfolio
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 BioFactura, Inc.
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Financial Overview
    • 13.5.4 Product Portfolio
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 WuXi AppTec
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Financial Overview
    • 13.6.4 Service Portfolio
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 LakePharma, Inc.
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Financial Overview
    • 13.7.4 Product Portfolio
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 General Electric
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Financial Overview
    • 13.8.4 Product Portfolio
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Lonza
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Financial Information
    • 13.9.4 Product Portfolio
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Corning Incorporated
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Financial Overview
    • 13.10.4 Product Portfolio
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms